Daniel A Lopes

US Patent:

20130011405, Jan 10, 2013

Filed:

Sep 12, 2012

Appl. No.:

13/612070

Inventors:

Li Long - Hercules CA, US
Mohammad Luqman - Danville CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Bao-Lu Chen - San Ramon CA, US
Xiaofeng Lu - Albany CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Sharon Lea Aukerman - Moraga CA, US
Daniel E. Lopes de Menezes - Emeryville CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 39/395
A61P 29/00
A61P 19/04
A61P 35/00
A61P 19/02
A61P 19/08
A61P 37/06
A61P 25/00
A61P 1/16
A61P 1/00
A61P 7/06
A61P 31/14
A61P 17/06
A61P 21/04
A61P 5/14
A61P 37/00
A61P 7/02
A61P 9/00
A61P 3/10
A61P 37/08
A61P 11/06
A61P 25/28
C12N 5/0781
A61K 39/44

US Classification:

4241391, 4241521, 4241781, 4241421, 4353722

Abstract:

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

US Patent:

20080254026, Oct 16, 2008

Filed:

Oct 31, 2007

Appl. No.:

11/932472

Inventors:

Li Long - Hercules CA, US
Mohammad Luqman - Danville CA, US
Asha Yabannavar - Lafayette CA, US
Isabel Zaror - El Cerrito CA, US
Bao-Lu Chen - San Ramon CA, US
Xiaofeng Lu - Albany CA, US
Sang Hoon Lee - Palo Alto CA, US
Deborah Hurst - Piedmont CA, US
Sharon Lea Aukerman - Mosaga CA, US
Daniel E. Lopes de Menezes - Emeryville CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 39/395
C07K 16/18
C12N 5/06
A61P 1/00
A61P 37/00
G01N 33/574
C07H 21/00

US Classification:

4241331, 5303877, 5303873, 435330, 536 235, 435377, 435375, 4241381, 435 723, 4241411, 4241421

Abstract:

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.